|
|
|
|
(+)-4-propyl-9-hydroxynaphthoxazine(PHNO)is a novel selective D2 agonist. The efficacy and safety of PHNO was studied in 10 Parkinsonian patients (Hoehn and Yahr Stage II or III)who continued to receive levodopa/ carbidopa.At the lowest dose administered(0.25 mg tid),nine of the 10 patients improved with respect to rigidity,bradykinesia and tremor.At this dose there was one dropout because of severe orthostasis.Although there was a trend towards improvement in motor scores with the higher doses(0.5- 1.0 mg tid),this was not statistically significant.At higher doses there were a total of four dropouts because of adverse effects such as nausea, vomiting and orthostatic hypotension.It appears that PHNO may prove to be efficacious in the treatment of Parkinson's disease. |
|